Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI (BASIK2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02917525 |
Recruitment Status : Unknown
Verified March 2018 by Maastricht University Medical Center.
Recruitment status was: Recruiting
First Posted : September 28, 2016
Last Update Posted : March 22, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Early development of calcified aortic valve disease (CAVD) is a commonly occurring complication in patients with a bicuspid aortic valve (BAV, an aortic valve consisting of two leaflets instead of three). In general, CAVD is characterized by progressive narrowing of the aortic valve, with involvement of altered calcium metabolism. CAVD progression in fact may lead to necessity of valve replacement, since to date, no other therapies have been shown effective in the treatment of CAVD.
The primary objective of our study is to test the hypothesis that supplementation of vitamin K2 will slow down the calcium metabolism in CAVD. Vitamin K2 is essential in the activation of matrix Gla Protein (MGP), an important inhibitory factor in the regulation of calcification.
In this randomized controlled trial, 44 patients will be allocated to either the vitamin K2 or placebo group. To assess the calcification process in a detailed manner in these patients, a Positron Emission Tomography (PET) scanner using a tracer (18F-fluoride [NaF]) that has been shown to bind to regions of newly developing microcalcification in aortic valve tissue is used.
We expect that vitamin K2 supplementation will reduce the calcium metabolism in the aortic valve on 18NaF-PET (primary endpoint) and slow progression of CAVD as measured by the calcium score on CT and echocardiography after 18 months (secondary endpoints), when compared to placebo.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Aortic Valve Stenosis Bicuspid Aortic Valve | Dietary Supplement: Vitamin K2 Other: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 44 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI (BASIK2): a Pilot Study |
Study Start Date : | August 2016 |
Estimated Primary Completion Date : | December 2019 |
Estimated Study Completion Date : | December 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Vitamin K2
22 patients will receive 360ug Vitamin K2 daily during 18 months.
|
Dietary Supplement: Vitamin K2 |
Placebo Comparator: Placebo
22 patients will receive placebo during 18 months.
|
Other: Placebo |
- Change in aortic valve calcium metabolism [ Time Frame: Measured at baseline and 6 months ]Change in calcium metabolism, measured as uptake of the 18F-NaF tracer on a 18F-NaF PET/CMR scan
- Change in aortic valve calcium score [ Time Frame: Measured at baseline, 6 and 18 months ]Change in aortic valve calcium score, measured on CT.
- Progression of aortic valve stenosis [ Time Frame: Measured at baseline, 6, 12 and 18 months ]Change of severity of aortic valve stenosis on echocardiography

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- known bicuspid aortic valve
- calcified mild to moderate aortic valve stenosis on prior echocardiography
- informed consent provided
Exclusion Criteria:
- absence of calcified aortic valve stenosis on echocardiography
- presence of severe aortic valve stenosis
- history of aortic valve repair or replacement
- accepted atrial fibrillation
- use of oral anticoagulants
- claustrophobia
- presence of a pacemaker, ICD or ferromagnetic materials in the body
- life expectancy <2 years
- Pregnancy (current or wish for near future)
- soy allergy
- use of vitamin K-containing supplements

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02917525
Contact: Bas Kietselaer, M.D., PhD | +31 (0)43 687 5096 | b.kietselaer@mumc.nl |
Netherlands | |
Maastricht UMC | Recruiting |
Maastricht, Netherlands, 6202 AZ | |
Contact: Bas Kietselaer, M.D., PhD +31 (0)43 3875093 b.kietselaer@mumc.nl | |
Contact: Bas Kietselaer, M.D. PhD +31 (0)43 3875093 b.kietselaer@mumc.nl | |
Sub-Investigator: Frederique Peeters, MD |
Principal Investigator: | Bas Kietselaer, M.D. PhD | Maastricht UMC |
Responsible Party: | Maastricht University Medical Center |
ClinicalTrials.gov Identifier: | NCT02917525 |
Other Study ID Numbers: |
METC152045 |
First Posted: | September 28, 2016 Key Record Dates |
Last Update Posted: | March 22, 2018 |
Last Verified: | March 2018 |
Calcium metabolism Matrix Gla Protein Vitamin K2 |
Aortic Valve Stenosis Heart Valve Diseases Constriction, Pathologic Pathological Conditions, Anatomical Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction Vitamin K Vitamin K 2 Vitamins |
Micronutrients Nutrients Growth Substances Physiological Effects of Drugs Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants |